^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    feladilimab (GSK3359609)

    i
    Company:
    GSK
    Drug class:
    ICOS agonist
    Related drugs:
    Apply
    Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1) (NCT02723955)
    Phase 1
    GlaxoSmithKline
    Completed
    Last update posted :
    12/27/2024
    Initiation :
    06/23/2016
    Primary completion :
    07/05/2023
    Completion :
    07/05/2023
    MSI • ICOS
    |
    MSI-H/dMMR
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • gemcitabine • paclitaxel • docetaxel • 5-fluorouracil • pemetrexed • Jemperli (dostarlimab-gxly) • bintrafusp alfa (M7824) • cobolimab (TSR-022) • feladilimab (GSK3359609) • GSK3174998
    Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) (NCT03739710)
    Phase 2
    GlaxoSmithKline
    Recruiting
    Last update posted :
    06/29/2023
    Initiation :
    01/24/2019
    Primary completion :
    07/08/2025
    Completion :
    07/08/2025
    BRAF
    |
    Yervoy (ipilimumab) • docetaxel • Zejula (niraparib) • Jemperli (dostarlimab-gxly) • cobolimab (TSR-022) • feladilimab (GSK3359609) • belrestotug (EOS-448) • nelistotug (GSK6097608)
    Study of a Combination of GSK1795091 and Immunotherapies in Subjects With Advanced Solid Tumors (NCT03447314)
    Phase 1
    GlaxoSmithKline
    Completed
    Last update posted :
    05/03/2023
    Initiation :
    03/26/2018
    Primary completion :
    07/01/2020
    Completion :
    03/11/2022
    CRP
    |
    Keytruda (pembrolizumab) • feladilimab (GSK3359609) • GSK1795091 • GSK3174998
    Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 1 (NCT05553808)
    Phase 2
    GlaxoSmithKline
    Completed
    Last update posted :
    01/19/2023
    Initiation :
    01/24/2019
    Primary completion :
    09/23/2021
    Completion :
    09/23/2021
    BRAF
    |
    docetaxel • feladilimab (GSK3359609)